Biolegend, 501301, Purified anti-human IL-7 Antibody, 50μg

IL-7 is a potent lymphoid cell growth factor which promotes the proliferation of pre-B cells, thymocytes, T cell progenitors, and mature T cells. IL-7 induces formation of LAK cells and CTLs, and can stimulate tumoricidal activity of monocytes and macrophages. IL-7 can induce upregulation of proinflammatory cytokines in myeloid cells. IL-7 is expressed by stromal cells. The BVD10-40F6 antibody can neutralize the bioactivity of natural or recombinant IL-7.
50μg
Verified Reactivity: Human
Antibody Type: Monoclonal
Host Species: Rat
Immunogen: E. coli - expressed, recombinant human IL-7
Formulation: Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation: The antibody was purified by affinity chromatography.
Concentration: 0.5 mg/ml
Storage & Handling: The antibody solution should be stored undiluted between 2°C and 8°C.
Application: ELISA Capture - Quality tested
Recommended Usage: Each lot of this antibody is quality control tested by ELISA assay. For ELISA capture applications, a concentration range of 2-6 µg/ml is recommended. To obtain a linear standard curve, serial dilutions of IL-7 recombinant protein ranging from 500 to 4 pg/ml are recommended for each ELISA plate. It is recommended that the reagent be titrated for optimal performance for each application.
Application Notes: ELISA or ELISPOT Capture1,2: The purified BVD10-40F6 antibody is useful as the capture antibody in a sandwich ELISA or ELISPOT assay, when used in conjunction with the Biotin anti-human IL-7 antibody (Cat. No. 506602) as the detecting antibody. The Ultra-LEAF™ purified antibody is suggested for ELISPOT capture.Neutralization1: The Ultra-LEAF™ purified antibody (Endotoxin <0.01 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for neutralization of human IL-7 bioactivity (Cat. No. 501305 & 501306).Additional reported applications (for the relevant formats) include: Western blotting.
Application References(PubMed link indicates BioLegend citation): Abrams J, et al. 1992. Immunol. Rev. 127:5. Abrams J. 1995. Curr. Prot. Immunol.. John Wiley and Sons New York. Unit 6.20.
Product Citations: Eberhardt F, et al. 2023. Int J Mol Med. 52:. PubMed Wallington JC, et al. 2018. J Allergy Clin Immunol. 2182:141. PubMed Haug V, et al. 2020. Transplantation. e260:104. PubMed Gilboa T, et al. 2020. Adv Healthc Mater. e2001111:. PubMed
RRID: AB_315164 (BioLegend Cat. No. 501302)
Structure: Cytokine; 20-28 kD (Mammalian)
Bioactivity: Proliferation of pre-/pro-B cells, thymocytes, T cells; formation of LAK cells, CTLs, stimulation of tumoricidal activity monocytes/macrophages; upregulate proinflammatory cytokines in myeloid cells
Cell Sources: Adherent bone marrow stromal cells, thymic stromal cells, spleen, keratinocytes
Cell Targets: Progenitor B and T cells; CD4-CD8- thymocytes; megakaryocytes
Receptors: Heterodimer IL-7Rα (CD127); γ-subunit (CD132) in common with IL-2R, IL-4R, IL-13R, IL-15R
Biology Area: Immunology
Molecular Family: Cytokines/Chemokines
Antigen References: 1. Fitzgerald K, et al. Eds. 2001. The Cytokine FactsBook. Academic Press San Diego. 2. Park L, et al. 1992. Adv. Exp. Med. Biol. 323 125. 3. Melchers F, et al. 1992. Adv. Exp. Med. Biol. 323 111.
Regulation: Downregulated by TGF-β
Gene ID: 3574
UniProt: View information about IL-7 on UniProt.org
Clone: BVD10-40F6
Regulatory Status: RUO
Other Names: Interleukin-7, Lymphopoietin-1 (LP-1), Pre-B cell growth factor, Thymocyte growth factor
Isotype: Rat IgG1, κ